The WarfarinAspirin Symptomatic Intracranial Disease(WASID) Trial, funded by the National Institute of NeurologicalDisorders and Stroke and reported by Chimowitz et al.1 in thisissue of the Journal, was a careful comparison of these twotherapies in patients with cerebrovascular events attributedto intracranial atherosclerosis. The WASID Trial, in concertwith other, smaller studies,2,3 clearly shows that symptomaticintracranial atherosclerotic stenosis is a marker of extremelyaggressive vascular disease. Ischemic stroke, brain hemorrhage,or death from vascular causes other than stroke occurred withintwo years in approximately 22 percent of the patients, whetherthey were treated with high-dose aspirin . . . [Full Text of this Article]
Source Information
From the Stroke Service, Massachusetts General Hospital, Boston.
This article has been cited by other articles:
Kasner, S. E., Lynn, M. J., Chimowitz, M. I., Frankel, M. R., Howlett-Smith, H., Hertzberg, V. S., Chaturvedi, S., Levine, S. R., Stern, B. J., Benesch, C. G., Jovin, T. G., Sila, C. A., Romano, J. G., for the Warfarin Aspirin Symptomatic Intracranial,
(2006). Warfarin vs aspirin for symptomatic intracranial stenosis: Subgroup analyses from WASID.. Neurology
67: 1275-1278
[Abstract][Full Text]
(2005). Warfarin vs. Aspirin for Symptomatic Intracranial Arterial Stenosis. JWatch Neurology
2005: 2-2
[Full Text]
(2005). Warfarin or Aspirin for Intracranial Arterial Stenosis?. JWatch General
2005: 4-4
[Full Text]